Ensysce Biosciences Statistics
Share Statistics
Ensysce Biosciences has 2.37M
shares outstanding. The number of shares has increased by 176.49%
in one year.
| Shares Outstanding | 2.37M |
| Shares Change (YoY) | 176.49% |
| Shares Change (QoQ) | 7.68% |
| Owned by Institutions (%) | 0% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 90 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 344.43K, so 14.53% of the outstanding
shares have been sold short.
| Short Interest | 344.43K |
| Short % of Shares Out | 14.53% |
| Short % of Float | 14.69% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -1.78 and the forward
PE ratio is -45.2.
Ensysce Biosciences's PEG ratio is
0.71.
| PE Ratio | -1.78 |
| Forward PE | -45.2 |
| PS Ratio | 2.73 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | 0 |
| PEG Ratio | 0.71 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Ensysce Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.42,
with a Debt / Equity ratio of 0.
| Current Ratio | 2.42 |
| Quick Ratio | 2.42 |
| Debt / Equity | 0 |
| Debt / EBITDA | -0.04 |
| Debt / FCF | n/a |
| Interest Coverage | -5.22 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $744,290.14 |
| Profits Per Employee | $-1,141,032.14 |
| Employee Count | 7 |
| Asset Turnover | 0.93 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -75.06% in the
last 52 weeks. The beta is 1.1, so Ensysce Biosciences's
price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | -75.06% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 5.4 |
| Relative Strength Index (RSI) | 44.56 |
| Average Volume (20 Days) | 1,731,649 |
Income Statement
In the last 12 months, Ensysce Biosciences had revenue of 5.21M
and earned -7.99M
in profits. Earnings per share was -4.57.
| Revenue | 5.21M |
| Gross Profit | 5.21M |
| Operating Income | -6.73M |
| Net Income | -7.99M |
| EBITDA | -6.73M |
| EBIT | -9.28M |
| Earnings Per Share (EPS) | -4.57 |
Full Income StatementBalance Sheet
The company has 3.5M in cash and 301.66K in
debt, giving a net cash position of 3.2M.
| Cash & Cash Equivalents | 3.5M |
| Total Debt | 301.66K |
| Net Cash | 3.2M |
| Retained Earnings | -129,544.3B |
| Total Assets | 4.61M |
| Working Capital | 2.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -7,502.7B
and capital expenditures 0, giving a free cash flow of -7,502.7B.
| Operating Cash Flow | -7,502.7B |
| Capital Expenditures | n/a |
| Free Cash Flow | -7,502.7B |
| FCF Per Share | -4295637.32 |
Full Cash Flow StatementMargins
Gross margin is 100%, with operating and profit margins of -129.18% and -153.3%.
| Gross Margin | 100% |
| Operating Margin | -129.18% |
| Pretax Margin | -153.3% |
| Profit Margin | -153.3% |
| EBITDA Margin | -129.18% |
| EBIT Margin | -129.18% |
| FCF Margin | -144004901.31% |
